

October 13, 2020



Brain Scientific Seeks FDA Approval of Next-Gen NeuroCap™ EEG Cap Amidst New Data on Neurological Problems in COVID Patients

NEW YORK, Oct. 13, 2020 (GLOBE NEWSWIRE) -- via [NewMediaWire](#) -- [Brain Scientific Inc.](#) (OTCQB: [BRSE](#)), a neurology-focused medical device and software company, has submitted a premarket 510(k) application to the United States Food and Drug Administration for its next generation NeuroCap™ device. NeuroCap™ is an advanced Electroencephalogram (EEG) electrode array used to obtain rapid EEGs in hospitals, clinics and rural areas where medical resources may be limited.

“This next generation NeuroCap is a hospital-grade disposable EEG headset that has 22 electrodes and 19 active EEG channels. We use velcro for better adhesion in the new cap. The device is designed for broader use - in addition to intensive care units and ERs,” said **Irina Nazarova, Marketing Director at [Brain Scientific](#)**.

NeuroCap™ can be applied in just 5 minutes and changed with each patient, removing the need to disinfect between uses. It is compatible with 3rd party amplifiers of EEG signals. Before applying for the FDA approval, Brain Scientific has evaluated the device for safety and performance according to ISO and ANSI/AAMI EC12: 2000 Disposable ECG electrodes standards.

The global pandemic is still raging, and new studies [show](#) more than 80% of hospitalized COVID-19 patients have neurological symptoms, which could require EEG testing. Additionally, there is an urgent need to limit contact between EEG technicians and patients in emergency rooms, ICUs, and clinical research facilities.

The Company believes that disposable EEG headsets represent a large market opportunity, estimating that approximately [5 million patients in US](#) emergency departments and ICUs are subject to seizures and could benefit from routine EEG tests. The Company’s data implies that one [in 26 people](#) in the US will be diagnosed with epilepsy at some point in their life, while [only 254 of 6,210 US hospitals](#) are Level 4 epilepsy centers with 24/7 EEG services.

About Brain Scientific

[Brain Scientific](#) is a commercial-stage healthcare company with two FDA-cleared products, providing next-gen solutions to the neurology market. The Company’s smart diagnostic

devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about our corporate strategy, devices or for investor relations please visit: www.brainscientific.com or email us at info@memorymd.com.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek” or “project” or the negative of these words or other variations on these words or comparable terminology. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates, and assumptions, and are subject to several risks and uncertainties and other influences, many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand its business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.

Den Serikov
info@memorymd.com



Source: Brain Scientific